Novel Photographic AI Tool Aims to Predict Anti-PD-1 Response in Metastatic Melanoma — French Trial Recruiting 700 Patients

References

1. 1.Alexandrov, L. B., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A., Behjati, S., Biankin, A. V., ... & Stratton, M. R. (2013). Signatures of mutational processes in human cancer. Nature, 500(7463), 415-421. https://doi.org/10.1038/nature12477
2. 2.Australian Institute of Health and Welfare. (2023). Cancer in Australia 2023. AIHW. https://www.aihw.gov.au/reports/cancer/cancer-in-australia-2023
3. 3.Chan, T. A., Yarchoan, M., Jaffee, E., Swanton, C., Quezada, S. A., Stenzinger, A., & Peters, S. (2019). Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Annals of Oncology, 30(1), 44-56. https://doi.org/10.1093/annonc/mdy495
4. 4.Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Rutkowski, P., Lao, C. D., ... & Wolchok, J. D. (2019). Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. New England Journal of Medicine, 381(16), 1535-1546. https://doi.org/10.1056/NEJMoa1910836
5. 5.Nantes University Hospital. (2023). Generation of an Artificial Intelligence Algorithm Based on the Analysis of Melanoma Peri-scar Dermatoheliosis, as a Predictive Factor of Response to Anti-PD-1. ClinicalTrials.gov. NCT05856565. https://clinicaltrials.gov/study/NCT05856565
6. 6.Robert, C., Ribas, A., Schachter, J., Arance, A., Grob, J. J., Mortier, L., ... & Long, G. V. (2019). Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncology, 20(9), 1239-1251. https://doi.org/10.1016/S1470-2045(19)30388-2
7. 7.Yarchoan, M., Hopkins, A., & Jaffee, E. M. (2017). Tumor mutational burden and response rate to PD-1 inhibition. New England Journal of Medicine, 377(25), 2500-2501. https://doi.org/10.1056/NEJMc1713444